ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Imbruvica/Gazyva combo improves PFS in CLL patients
pharmatimes
July 11, 2018A combination of AbbVie/Johnson & Johnson’s Imbruvica and Roche’s Gazyva has taken a step closer to becoming first chemotherapy-free CD20 combination for first-line treatment of chronic lymphocytic leukaemia (CLL), after showing promise in a late-stage cl -
Imbruvica/Gazyva combo improves PFS in CLL patients
pharmatimes
July 11, 2018A combination of AbbVie/Johnson & Johnson’s Imbruvica and Roche’s Gazyva has taken a step closer to becoming first chemotherapy-free CD20 combination for first-line treatment of chronic lymphocytic leukaemia (CLL), after showing promise in a late-stage cl -
Imbruvica/Gazyva combo improves PFS in CLL patients
pharmatimes
July 11, 2018A combination of AbbVie/Johnson & Johnson’s Imbruvica and Roche’s Gazyva has taken a step closer to becoming first chemotherapy-free CD20 combination for first-line treatment of chronic lymphocytic leukaemia (CLL), after showing promise in a late-stage cl
Pharma Sources Insight January 2025
